Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on September 23, 2019. The registrant is a Delaware corporation with its principal executive offices in Austin, Texas, and its common stock trades on the Nasdaq Global Market under the symbol "AGLE". The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a named executive officer:
- Resignation: James Wooldridge, M.D., resigned as Chief Medical Officer (CMO), effective October 10, 2019.
- Interim Appointment: Anthony G. Quinn, M.B. Ch.B., Ph.D., the Chief Executive Officer, will assume CMO responsibilities until a permanent replacement is identified.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the operational impact of the executive departure. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the timeline for the recruitment of a permanent Chief Medical Officer to replace Dr. Wooldridge.
- Confirm the impact of the CMO transition on the company's clinical trial programs and regulatory filings.
- Review subsequent filings for any changes in executive compensation or board composition related to this departure.